The mission of Insilico Medicine is to extend healthy, productive longevity by transforming drug discovery and development with generative artificial intelligence, significantly reducing the time and cost of bringing life-saving medications to patients.
The company integrates two business models: providing AI-powered drug discovery services and software through its Pharma.AI platform (www.insilico.com/platform/) and developing its own pipeline of preclinical programs.
Their Pharma.AI platform consists of Biology42 PandaOmics, Chemistry42 and Medicine42 inClinico, designed to be integrated across the drug discovery and development process to efficiently identify novel drug targets, design de novo molecules against both novel and known targets, and optimise clinical development.
